CRT Discovery Laboratories

CRT Discovery Laboratories (CRT-DL) is the in-house drug discovery unit of Cancer Research Technology, the wholly-owned development and commercialisation arm of Cancer Research UK. Based at the Babraham Research Campus, Cambridge, and the London Bioscience Innovation Centre, CRT-DL comprises over 70 staff from both industrial and academic backgrounds.

New Biology to Collaborations to New Therapies

Contacts

Cancer Research UK Cancer Research Technologies (CRT)
Cancer Research UK Cancer Research Technologies (CRT)
Drug Discovery

CRT Discovery Laboratories (CRT-DL) is the in-house drug discovery unit of Cancer Research Technology, the wholly-owned development and commercialisation arm of Cancer Research UK. Based at the Babraham Research Campus, Cambridge, and the London Bioscience Innovation Centre, CRT-DL comprises over 70 staff from both industrial and academic backgrounds.

Our expertise spans cancer target validation and disease positioning, assay development and HTS, protein crystallography, medicinal chemistry, PK-PD and cancer models. Through our alliance approach CRT-DL aligns these key skills with internationally competitive academic research and the development capabilities of industry partners to maximise cancer patient benefit.

CRT-DL has an exclusive focus on establishing and prosecuting biologically-themed multi-project alliances with industry. We bring together the best minds in basic and clinical cancer research, the rigour and drive of pharmaceutical and biotech companies, and our in-house drug discovery and alliance management capabilities to deliver breakthrough medicines for cancer patients.

We’re uniquely placed to capitalise on the research and connections of our parent organisation Cancer Research UK, the world’s largest charitable funder of cancer research, and the strong links we’ve established with leading clinical and academic institutions, pharmaceutical companies and biotechs worldwide.